|
|
||||||||

* Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, and
Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
T. cruzi expresses trans-sialidase
(TS),4 a unique
pathogen-derived surface sialidase that transfers sialic acid residues
2,3-linked to
-galactopiranose (
Galp) on host donor
molecules to mucin-like acceptor glycoproteins (6, 7). In
the absence of a suitable acceptor, TS displays a typical hydrolytic
action similar to viral and bacterial sialidases (8). TS
is GPI-anchored to the parasite membrane, and can be released in fairly
high amounts into the serum during human acute T. cruzi
infection (9). Surface TS is required for mammalian cell
invasion (7, 10, 11), while soluble TS appears to be a
virulence factor that increases parasitemia and mortality of T.
cruzi-infected mice (12). Recent reports indicate
that soluble TS increases macrophage invasion by T. cruzi
through mitogen-activated protein (MAP) kinase signaling
(13), induces apoptosis in cells of the immune system
(14), and increases T cell responses in vitro through
activation of accessory cell function (15). However, the
interaction of TS with CD4+ T cells from normal
and T. cruzi-infected hosts was not investigated. In this
study, we report that soluble T. cruzi recombinant TS (rTS)
induces CD4+ T cell activation in vivo and
costimulates naive CD4+ T cells in vitro. In
CD4+ T cells from infected hosts, TS exacerbates
mitogenic responses and rescues T cells from activation-induced cell
death (AICD). By flow cytometry, an enzymatically inactive mutant TS
binds the highly sialylated mucin CD43 on the T cell surface, and CD43
engagement is required for costimulation and rescue from AICD.
Therefore, T. cruzi TS is a natural CD43 ligand with T
cell-activating properties and is a candidate molecule for induction of
immunopathology during T. cruzi infection.
| Materials and Methods |
|---|
|
|
|---|
Male BALB/c mice, ages 45 wk, were obtained from the Instituto Oswaldo Cruz (Instituto Oswaldo Cruz-Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil) animal facility. Mice were infected (105 parasites/0.1 ml s.c.) with chemically induced metacyclic trypomastigotes from T. cruzi clone Dm28c, obtained as described previously (16). Uninfected littermates were used as controls. CD43-/- and wild-type control mice (17) were a gift from Dr. M. Correa (Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil) and were infected with T. cruzi as above. Cells from infected mice were obtained 2125 days after infection. All experiments were conducted according to protocols approved by the Committee on Ethics and Regulations of Animal Use of the Instituto de Biofísica Carlos Chagas Filho.
Native trans-sialidase
Dm28c T. cruzi metacyclic trypomastigotes were
centrifuged, and the cell pellet was lysed at 4°C in 50 mM Tris-HCl,
2% Nonidet P-40, 0.1 mM PMSF, 5 µg/ml leupeptin, 0.1 mM
iodoacetamide, and 0.1 mM EDTA. The lysate was processed by affinity
chromatography on Sepharose 4B-Con A and eluted with
-methyl
mannoside (0.1 M). The eluate was applied to a Mono Q (HR 16/10),
followed by a Mono S (HR 5/5) column (Pharmacia Biotech, Uppsala,
Sweden), and the enzyme was eluted with a linear gradient of
NaCl (01 M). The homogeneity of the enzyme was evaluated by 10%
SDS-PAGE; it migrated as a band of
60 kDa.
Recombinant TS
rTS and inactive TS (irTS) containing the C-terminal repeats
were obtained from Escherichia coli MC1061
electrotransformed with plasmids containing either the wild-type TS
insert, TSREP.C (18), or the inactive mutant TS insert
bearing a Tyr342
His342
substitution, pTrcHisA (18). Bacteria were grown in
supplemented terrific broth medium in the presence of 100
µg/ml ampicillin. When the culture reached an
A600 of 1.5, 30 mg/L of
isopropyl-
-D-thiogalactoside was added and
incubation was continued overnight. Bacteria were lysed at 4°C in 20
mM Tris-HCl containing 2.0 mg/ml lysozyme, 2% Triton X-100, 0.1 mM
PMSF, 5.0 µg/ml leupeptin, 1.0 µg/ml trypsin inhibitor, and 0.1
µM iodoacetamide. Both rTS and irTS contained a poly(His) tag and
were purified as described by Buschiazzo et al. (19),
modified by Todeschini et al. (8), using
Ni2+ chelating chromatography on a HiTrap column
(Pharmacia Biotech) eluted with imidazol gradient (19).
The eluates were applied to Mono Q and Mono S columns as described
above. The homogeneity of the proteins was evaluated by 10% SDS-PAGE.
rTS and irTS were stored in 20 mM Tris-HCl buffer (pH 7.4) at 4°C
until use. For in vivo experiments and for cultures in the presence of
dendritic cells (DCs), rTS and irTS were passed through an
agarose-immobilized polymyxin B column (Sigma-Aldrich, St. Louis, MO)
to obtain a LPS-free preparation. The LPS content of TS preparations
was quantitated by the Limulus amebocyte lysate assay
(Charles River Endosafe, Charleston, SC) and was below detection. For
flow cytometry (FCM) and Western blotting analyses, irTS was FITC or
biotin conjugated as described elsewhere (20).
TS activity measurements
TS activity was assayed by incubating enzyme preparations in 5 mM cacodylate buffer (pH 7.0) in the presence of 0.25 µmol of 2,3-sialyllactose and 0.25 µmol of [D-glucose-1-14C]lactose (6). After incubation at 37°C for 30 min, the reaction mixture was diluted with 1 ml of water and applied to a column containing 1 ml of Dowex 2X8 (acetate form) equilibrated with water. [D-Glucose-1-14C]lactose was eluted by washing with 9 ml of distilled water, while sialylated [D-glucose-1-14C]lactose was eluted with 3 ml of 0.8 M ammonium acetate. The sialylated product was quantitated by beta scintillation counting (Beckman LS 6500; Beckman Coulter, Fullerton, CA). The enzyme concentration was adjusted to 1 mU/µg protein (1 U was defined as the amount of enzyme required to catalyze the incorporation of 1 µmol of sialic acid into N-acetyllactosamine per minute).
Antibodies
Anti-CD43 mAb S7, anti-CD45 mAb 16A, PE-labeled
anti-B7.2, anti-B220, anti-CD8, anti-MAC-1,
anti-CD16/32 mAb 2.4G2, FITC- or PE-labeled anti-CD4 and
anti-CD8 mAbs, and FITC-labeled anti-CD44 mAb were purchased
from BD PharMingen (San Diego, CA). Anti-
TCR H57.597 mAb was
obtained from American Type Culture Collection (Manassas, VA).
Anti-
TCR mAb 13D5 was kindly provided by Dr. E. M. Shevach
(National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, MD). Anti-mouse IgG conjugated to HRP
or avidin-peroxidase were purchased from Sigma-Aldrich. Fab fragments
of anti-CD43 mAb S7 (rat IgG2a) or anti-Ly6A/E mAb D7, an
isotype control mAb also reactive with T cells (21), were
produced with a commercial Fab preparation kit (Pierce, Rockford, IL).
Anti-extracellular signal-regulated kinase (ERK) 1/ERK-2 polyclonal Ab
and anti-goat IgG conjugated to HRP were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
In vivo activation assays
BALB/c mice were injected with 50 µl of a suspension containing 25 µg of endotoxin-free rTS, T. cruzi mucin, or PBS in IFA (Sigma-Aldrich) into the right hind footpads. Animals were sacrificed after 5 days and draining popliteal lymph nodes were removed. Cell suspensions (5 x 105 cells) were treated with anti-CD16/32 mAb (Fc block) for 5 min at 4°C, followed by addition (30 min, 4°C) of saturating (10 µg/ml) doses of PE-labeled anti-CD4, plus FITC-labeled anti-CD44 mAbs, in sorting buffer (PBS/2% FCS and 0.02% NaN3). Cells were analyzed by FCM using a BD Biosciences FACSCalibur flow cytometer (Mountain View, CA).
Cell cultures
Primary T cell-enriched suspensions from naive or infected mice
were obtained by nylon wool filtration of unfractionated splenocytes
depleted of RBC by treatment with Tris-buffered ammonium chloride.
Purified CD4+ T cells were nylon-nonadherent
cells treated with anti-CD8 mAb for 30 min at 4°C, followed by
anti-rat Ig
-chain mAb MAR 18.5 plus 10% rabbit low-Tox
complement (Cedarlane Laboratories, Hornby, Ontario, Canada) for 45 min
at 37°C. These cells still contained 510% endogenous non-T cells,
which served as APCs in T cell activation assays. Highly purified
CD4+ T cells (>97% CD4+)
were obtained from nylon-nonadherent splenocytes depleted of
CD8+, NK cells, 
T cells,
B220+, and MAC-1+ cells by
magnetic cell sorting using a mAb mixture (BD PharMingen)
supplemented with anti-
TCR mAb 13D5, followed by MAR 18.5
mAb, and adsorbed with anti-mouse Ig-coated magnetic beads (Biomag;
Advanced Magnetics, Cambridge, MA). DCs were isolated from the spleens
of naive BALB/c mice by a modification of a previously described method
(22). Briefly, splenocytes were resuspended in DMEM (Life
Technologies, Rockville, MD) supplemented with 2 mM glutamine, 5
x 10-5 M 2-ME, 10 µg/ml gentamicin, 1 mM
sodium pyruvate, and 0.1 mM MEM nonessential amino acids (culture
medium), plus 5% FBS (Life Technologies), and allowed to adhere to
plastic petri dishes. After 2 h at 37°C, nonadherent cells were
removed and adherent cells were incubated overnight at 37°C.
Resulting nonadherent cells were depleted of contaminating B cells and
macrophages by treatment with anti-B220 plus anti-MAC-1 mAbs,
followed by MAR 18.5, and separated by magnetic cell sorting using
anti-mouse/rat Ig-coated magnetic beads (Biomag), and were highly
enriched in DCs. The cells were identified as DC by microscopic
examination and by FCM analysis with FITC-labeled 33D1 mAb, prepared as
described previously (20).
Proliferation and viability assays
CD4+ T cells (2 x
105 or 2 x 106) were
resuspended in culture medium containing 1% Nutridoma (SP-Nutridoma;
Boehringer Mannheim, Indianapolis, IN) instead of FBS. Cultures (0.2 ml
or 1.0 ml) were established in 96- or 24-well vessels (Corning Glass
Works, Corning, NY), respectively. All cultures, except those in the
presence of DCs (5 x 104 DCs/0.2 ml well),
were treated with PMA (Sigma-Aldrich) at 0.5 ng/ml. The stimuli used
were: anti-
TCR mAb H57.597 (10% v/v culture supernatant),
native or rTS (15 µ (µg)/ml), irTS (15 µg/ml), anti-CD43 Fab,
control Fab fragment (50 µg/ml), and T. cruzi mucin (15
µg/ml). Mucin from T. cruzi was purified from G strain
epimastigotes as described elsewhere (23). For
proliferation assays, cultures were incubated for 3 days at 37°C and
7% CO2 in a humid atmosphere and pulsed with 0.5
µCi of tritiated thymidine ([3H]TdR, 5.0
Ci/mmol; Sigma-Aldrich) 18 h before harvest. Cultures were
terminated with a semiautomated cell-harvesting device and the amount
of [3H]TdR incorporated into DNA was assessed
by liquid scintillation spectroscopy. Results shown are mean and SE of
cultures done in triplicate. Highly purified CD4+
T cells were stimulated with a submitogenic dosage of anti-CD3 mAb
145-2C11 (1/5000 v/v dilution of ascites fluid) coated on 96-well
flat-bottom wells in the presence or absence of TS, with or
without PMA. Supernatants were collected after 48 h. Proliferation
was measured in sister cultures after 3 days. For viability assays,
CD4+ T cells from T. cruzi-infected
mice were cultured as above. After 20 h, cultures were dispersed
and counted by trypan blue exclusion. Mean viable cell recovery in
unstimulated (PMA alone) cultures was taken as reference. Percent cell
loss (the reciprocal of remaining viable cells) was calculated for each
individual well according to the formula: percent cell loss =
100 - ((viable cell number in stimulated culture) x
100/(viable cell number with PMA alone)). Mean and SE of triplicate
cultures are shown. Negative values of cell loss indicate lack of AICD
and a block of spontaneous death; positive values indicate
AICD.
ELISA
For cytokine production, CD4+ T cells
(1 x 106/1.0 ml) were stimulated and
cultured as above. Levels of IFN-
, TNF-
, IL-2, and IL-4 were
determined in culture supernatants harvested 24 (for IL-2) or 48 h
after initiation and kept at -20°C until assayed. Cytokine levels
were measured in sandwich ELISA using pairs of specific mAbs, one of
which was biotinylated (BD PharMingen) and developed with
streptavidin-alkaline phosphatase (BD PharMingen) and
p-nitrophenylphosphate substrate.
Western blotting and TS-labeling analyses
For Western blotting, CD4+ T cells were obtained and cultured as above. After 4 h, 1 x 107 cells were pooled, centrifuged, and washed twice in ice-cold PBS. The cell pellet was resuspended in 0.4 ml of ice-cold lysis buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM 1,-bis(p-chlorophenyl)-2,2,2-trichloroethane plus protease inhibitors (1 mM PMSF, 5 µg/ml leupeptin, and 0.1 µM iodoacetamide), and incubated at 4°C for 1 h. The nuclear fraction was pelleted by centrifugation and the supernatant was referred to as cytosolic extract (24). The nuclear pellet was washed and resuspended in 0.1 ml of ice-cold lysis buffer supplemented with protease inhibitors plus 1% Triton X-100 and incubated at 4°C for 1 h (nuclear extract). Total protein was measured, 30 µg of protein/lane was electrophoresed on 10% SDS-PAGE at 100 mV, and electrotransferred to a nitrocellulose membrane. After overnight incubation (5% milk in TBS and 0.2% Tween 20), the blot was reacted with anti-ERK-1/2 Ab, followed by HRP-conjugated anti-goat IgG. The reaction was detected using ECL in Hyperfilm-ECL according to the manufacturer (Amersham, Arlington Heights, IL).
FCM analysis of TS binding to lymphocytes
For TS-binding studies, splenic naive CD4+ T cells were washed in sorting buffer (containing 2% BSA instead of FBS) and incubated with Fc block (10 µg/ml), followed by addition of 50 µg/ml unlabeled irTS, anti-CD43 mAb S7, or anti-CD45 mAb 16A. After 30 min at 4°C, FITC-conjugated irTS (10 µg/ml) was added for 30 min at 4°C. Cells were then washed and resuspended in sorting buffer containing 2% paraformaldehyde. Lymphocytes were gated by forward and side scatter parameters, and 10,000 cells were analyzed on a FACSCalibur system using CellQuest software.
Statistics
Data were analyzed by Students t test for independent samples using a SigmaPlot for Windows (version 4.01) package. Differences with a p value of <0.05 were considered to be significant.
| Results |
|---|
|
|
|---|
To examine whether T. cruzi TS activates host
CD4+ T cells in vivo, rTS emulsified in IFA was
injected into the footpads of naive BALB/c mice. After 5 days, cell
number in lymph nodes draining TS was 2.6-fold higher than in control
nodes draining PBS-IFA (data not shown). Injection of rTS induced T
cell activation in vivo, as measured by an increase in percentage and
absolute number of CD4+ T cells expressing a
CD44high phenotype, compared with control T cells
from nodes draining PBS-IFA (Fig. 1
).
Furthermore, injection of T. cruzi mucin emulsified in IFA
did not result in enlarged lymph nodes (data not shown), and
CD4+ T cells from draining lymph nodes did not
express enhanced levels of CD44 (Fig. 1
).
|
The mechanism of T cell stimulation by TS was investigated in
vitro using naive BALB/c splenic CD4+ T
lymphocytes (containing around 10% endogenous APCs) as responder
cells. Both native and rTS failed to induce T cell mitogenesis.
However, in the presence of PMA as costimulus, both native and rTS
induced polyclonal CD4+ T lymphocyte activation
in vitro, as measured by a dose-dependent increase of T cell
proliferation (Fig. 2
A). The
comitogenic effect of rTS, but not of anti-TCR mAb, was selectively
eliminated by adding the soluble TS substrate
N-acetyllactosamine (Fig. 2
B). At suboptimal (3
µg/well), but not optimal, concentrations, TS (both native and
recombinant) and anti-TCR mAb synergized to induce
CD4+ T cell proliferation (Fig. 2
C).
In addition, rTS also costimulated CD4+ T cells
from T. cruzi-infected mice (data not shown). An
enzymatically inactive form of TS (irTS), containing a
Tyr342
His342
substitution (18), induced naive T cell activation in the
presence of PMA (Fig. 2
D), suggesting that sialic acid
transfer is not required for T cell costimulation. Under the same
conditions, a GPI anchor-containing mucin fraction from T.
cruzi did not induce T cell mitogenesis (Fig. 2
D).
Addition of rTS to naive CD4+ T cells increased
IL-2 secretion driven by TCR ligation (data not shown). Although TCR
stimulation induced little or no secretion of TNF-
by T cells,
costimulation by rTS induced TNF-
secretion (Fig. 2
E).
Secretion of TNF-
was eliminated by soluble TS substrate
N-acetyllactosamine (Fig. 2
E). To investigate
whether exposure of CD4+ T cells to TS affected
mitogenic intracellular signaling, we tested by immunoblotting the
nuclear translocation of MAP kinases ERK-1 and ERK-2 from
CD4+ T cell extracts (Fig. 3
). Both rTS and TCR ligation induced
nuclear translocation of ERK-1/2 in naive CD4+ T
lymphocytes (Fig. 3
, lanes 2 and 3), compared
with treatment with PMA alone (Fig. 3
, lane 1). A synergism
between rTS and TCR signaling was seen with nuclear MAP kinase
translocation (Fig. 3
, lane 4).
|
|
|
|
CD43 and CD45 are mucins that express high amounts of sialic acid
and are abundantly expressed by T cells (26, 27). These
surface Ags could potentially interact with TS. Since irTS costimulates
T cells and since irTS acts like a lectin on RBC (18), we
used FITC-labeled irTS and FCM to investigate the interaction of TS
with host T cells. Naive splenic CD4+ T cells
were subjected to different pretreatments and subsequently stained with
FITC-irTS. Binding of FITC-irTS to CD4+ T cells
was prevented by 96% by pretreatment with excess (50 µg/ml)
unlabeled irTS (Fig. 6
). Although
pretreatment with excess (50 µg/ml) anti-CD45 mAb 16A gave only
marginal inhibition of FITC-irTS binding (17% reduction in median
channel fluorescence), pretreatment with anti-CD43 mAb S7 blocked
FITC-irTS binding almost completely, i.e., by 90% (Fig. 6
). In
agreement with these data, both irTS and anti-CD43 mAb S7 bound the
same 115-kDa protein band on CD4+ T cell extracts
expected for CD43, while anti-CD45 mAb 16A recognized a single
190-kDa band expected for the CD45 isoform expressed by splenic
CD4+ T cells (data not shown). These results
suggest that T. cruzi irTS binds CD43.
|
To investigate whether CD43 is involved in the costimulatory
effects of TS on CD4+ T cells, we made monovalent
anti-CD43 Fab fragments to act as specific antagonists of CD43
engagement. We tested Fab fragments from anti-CD43 mAb S7 and from
a rat isotype control mAb (D7; IgG2a) that binds Ly-6A/E molecules on T
cells (21). Addition of anti-CD43 Fab, but not control
Fab fragment, completely blocked costimulatory effects of T.
cruzi rTS on naive CD4+ T cells in the
absence (Fig. 7
A) or in the
presence of TCR stimulation (Fig. 7
B). We also tested the
effect of anti-CD43 Fab on responses induced against syngeneic DCs.
Anti-CD43 Fab had no effect on syngeneic T cell mitogenesis induced by
DCs alone (data not shown), but blocked the costimulatory increase
elicited by rTS by 76%, while control Fab had no effect (Fig. 4
).
These results suggest that CD43 is involved in TS-mediated
costimulation.
|
| Discussion |
|---|
|
|
|---|
2,3
linked to
Galp in O-linked sialyloligosaccharides
(26) makes CD43 a candidate receptor for T.
cruzi TS. Cross-linkage of CD43 induces DC maturation
(29) and transduces costimulatory signals to T cells
synergizing with TCR stimulation (30). Signaling through
CD43 induces Vav tyrosine phosphorylation, activation of the MAP kinase
cascade, Ca2+ mobilization, and increased IL-2
secretion (31). Costimulation by CD43 could result from
release of inhibitory signals imposed on TCR. It has been described
that CD43 inhibits TCR signaling at the immunological synapse, and
active exclusion to a distal site is required to increase cytokine
production (32). We report here that injection of T.
cruzi TS activates host CD4+ T cells in vivo
and demonstrate that TS binds and costimulates T cells through
interaction with CD43. It is possible that other viral and bacterial
sialidases share biological properties with T. cruzi TS.
Whether immunopotentiating and mitogenic effects of Vibrio
cholerae sialidase (33) and influenza A virus
particles are also mediated by interaction with CD43 should be
investigated. CD43 is a neutrophil receptor for influenza A particles,
partially responsible for virus-induced neutrophil deactivation
(34). CD43 was also implicated in macrophage invasion by
Mycobacterium tuberculosis (35).
Molecular modeling studies demonstrated that TS folds into two
structurally distinct domains: 1) a
-propeller fold expressing
sialic acid and
Galp binding sites, where both the hydrolysis and
transfer reactions take place; and 2) a C-terminal lectin-like domain
which is probably involved in carbohydrate recognition
(36). Our data demonstrated that both TS and an
enzymatically inactive TS mutant costimulate T cells, indicating that
sialic acid transfer is not required for the immunopotentiating effects
of TS and, instead, rTS and irTS may be acting as a lectin. Recent
studies indicate that irTS displays a
Galp binding site and thus it
behaves like a lectin (18). Using nuclear magnetic
resonance techniques, we recently found that TS binds sialic acid
residues
2,3 linked to
galactose.5 It has
been suggested that TS could form trimers in solution
(37). Cross-linkage of CD43 by TS trimers could explain
delivery of activating signals to T cells, since CD43 associates with
tyrosine kinases (38) and CD43 engagement initiates
signal-transducing cascades in T cells (31). On the other
hand, CD43 inhibits TCR signaling at sites of interaction with APCs and
exclusion of CD43 to a site distal to the synapse is required for
optimal T cell responses (32). Therefore, it is also
possible that interaction with TS increases CD43 exclusion from the
synapse amplifying T cell responses. However, TS binding to CD43
protects T cells from TCR-induced apoptosis. This result suggests that
signals delivered by CD43 itself must be involved in protection.
Furthermore, our data indicated that rTS and irTS transduce signals
directly to T cells in the absence of APCs. TS and its enzymatically
inactive catalytic domain also protect the PC12 neuronal cell line from
apoptosis (39). Several ligands have been proposed for
CD43, including ICAM-1 (40), galectin-1 (41),
class I MHC (42), E-selectin (43), and
macrophage sialoadhesin (44). Our studies suggest that TS
is a microbial ligand for CD43, potentially involved in pathological
effects of the infection.
Although CD43 plays a pivotal role, the molecular basis of TS-induced T lymphocyte activation needs to be further elucidated. First, the requirement of PMA for costimulation by TS suggests that CD43 must be primed, perhaps by phosphorylation, to signal. It has been described that phorbol ester increases CD43 phosphorylation (38). Second, TS costimulated T cell activation by syngeneic DCs, suggesting that TS could exacerbate homeostatic syngeneic T cell-DC interactions in vivo. In support of this possibility, CD43 cross-linkage also increases interactions of DCs with syngeneic T cells (45). However, other potential explanations for the immunostimulatory effect of TS remain. Since generation of T cell clones specific for TS has been described (46), processing of TS could create multiple TS epitopes, stimulating a large number of T cells. Recently, Gao and Pereira (15) suggested that TS costimulates T cells indirectly through effects on accessory cells. Although we cannot discard that TS increases the costimulatory activity of APCs, we have provided evidence that TS binds to T cells and costimulates highly purified CD4+ T cells in the absence of APCs. TS induces purified CD4+ T cells to spread over anti-CD3-coated surfaces, which could be the basis for increased TCR engagement and costimulated responses. Different from the latter study (15), we found that increased T cell responses, as well as rescue from apoptosis, depended on CD43. We have used a different cloned rTS and higher doses of the enzyme, which could explain the differences.
Our data raise the possibility that TS and other noncatalytic members
of the TS multigene family could be the parasite molecules responsible
for the polyclonal T cell activation in T. cruzi infection.
Polyclonally activated CD4+ T cells from T.
cruzi infection undergo AICD by apoptosis (28). Here,
we have demonstrated that TS rescues T cells from AICD through a
mechanism dependent on CD43 engagement. AICD plays an important role in
down-regulation of peripheral T cell responses (47).
Rescue from AICD could amplify the host response to T. cruzi
infection and increase cytokine production, e.g., TNF-
and IL-4. It
is not surprising that a costimulatory molecule like TS protects T
cells against apoptosis and up-regulates cytokine production. However,
it is a paradox that TS also plays a virulence role in infection
(12). One possibility would be that TS, like
superantigens, rapidly induces T cell anergy following
immunostimulation. Alternatively, TS could promote T cell apoptosis
(14) or anergy indirectly, e.g., through increased NO
production.
In summary, we found that T. cruzi TS binds and activates host CD4+ T lymphocytes in vivo and in vitro. If these findings can be extended to human cells, TS becomes a candidate molecule to be targeted to block immunopathology and to improve efficacy of vaccination in Chagas disease.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Current address: Departamento de Bioquímica, Instituto de Biologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. ![]()
3 Address correspondence and reprint requests to Dr. George A. DosReis, Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho da Universidade Federal de Rio de Janeiro, Centro de Ciências da Saúde, Bloco G, Ilha do Fundão, Rio de Janeiro, RJ 21944-970, Brazil. E-mail address: gdosreis{at}biof.ufrj.br ![]()
4 Abbreviations used in this paper: TS, trans-sialidase; rTS, recombinant TS; irTS, inactive rTS;
Galp,
-galactopiranose; AICD, activation-induced cell death; DC, dendritic cell; FCM, flow cytometry; MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase. ![]()
5 A. R. Todeschini, M. F. Girard, J. M. Wieruszeski, G. A. DosReis, L. Mendonça-Previato, and J. O. Previato. Trans-sialidase from Trypanosoma cruzi binds host T lymphocytes in a lectin manner. Submitted for publication. ![]()
Received for publication March 30, 2001. Accepted for publication March 12, 2002.
| References |
|---|
|
|
|---|
-galactose binding activity. Glycobiology 9:581.This article has been cited by other articles:
![]() |
J. Mucci, E. Mocetti, M. S. Leguizamon, and O. Campetella A Sexual Dimorphism in Intrathymic Sialylation Survey Is Revealed by the trans-Sialidase from Trypanosoma cruzi J. Immunol., April 15, 2005; 174(8): 4545 - 4550. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Tribulatti, J. Mucci, N. Van Rooijen, M. S. Leguizamon, and O. Campetella The trans-Sialidase from Trypanosoma cruzi Induces Thrombocytopenia during Acute Chagas' Disease by Reducing the Platelet Sialic Acid Contents Infect. Immun., January 1, 2005; 73(1): 201 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Woronowicz, K. De Vusser, W. Laroy, R. Contreras, S. O. Meakin, G. M. Ross, and M. R. Szewczuk Trypanosome trans-sialidase targets TrkA tyrosine kinase receptor and induces receptor internalization and activation Glycobiology, November 1, 2004; 14(11): 987 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tong, E. J. Allenspach, S. M. Takahashi, P. D. Mody, C. Park, J. K. Burkhardt, and A. I. Sperling CD43 Regulation of T Cell Activation Is Not through Steric Inhibition of T Cell-APC Interactions but through an Intracellular Mechanism J. Exp. Med., May 3, 2004; 199(9): 1277 - 1283. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Todeschini, W. B. Dias, M. F. Girard, J.-M. Wieruszeski, L. Mendonca-Previato, and J. O. Previato Enzymatically Inactive trans-Sialidase from Trypanosoma cruzi Binds Sialyl and {beta}-Galactopyranosyl Residues in a Sequential Ordered Mechanism J. Biol. Chem., February 13, 2004; 279(7): 5323 - 5328. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Todeschini, M. F. Girard, J.-M. Wieruszeski, M. P. Nunes, G. A. DosReis, L. Mendonca-Previato, and J. O. Previato trans-Sialidase from Trypanosoma cruzi Binds Host T-lymphocytes in a Lectin Manner J. Biol. Chem., November 22, 2002; 277(48): 45962 - 45968. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE |